Overcoming Resistance Against HER2-Targeting Agents in Fifth-Line Therapy: Is There Still a Place for Bevacizumab in HER2+ Breast Cancer?

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2013.09.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine
Medicine
2012English

Src, a Potential Target for Overcoming Trastuzumab Resistance in HER2-positive Breast Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2014English

Targeted Therapy for HER2 Positive Breast Cancer

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

HER2 Signaling Pathway Activation and Response of Breast Cancer Cells to HER2-targeting Agents Is Dependent Strongly on the 3D Microenvironment

Breast Cancer Research and Treatment
Cancer ResearchOncology
2009English

Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer

Scientific Reports
Multidisciplinary
2017English

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Her2 Cross Talk and Therapeutic Resistance in Breast Cancer

Frontiers in Bioscience - Landmark
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2008English

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

Breast Care
SurgeryOncology
2016English

Efficacy and Safety of HER2-Targeted Agents for Breast Cancer With HER2-Overexpression: A Network Meta-Analysis

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy